{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:11:45Z","timestamp":1761581505011},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.lungcan.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T19:02:15Z","timestamp":1483988535000},"page":"49-51","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?"],"prefix":"10.1016","volume":"105","author":[{"given":"Aaron Scott","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lungcan.2017.01.004_bib0005","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.lungcan.2017.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2017.01.004_bib0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2017.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2017.01.004_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40259-016-0187-0","article-title":"Advances in the treatment of non-small cell lung cancer: focus on nivolumab, pembrolizumab, and atezolizumab","volume":"30","author":"Leventakos","year":"2016","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.lungcan.2017.01.004_bib0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cpt.360","article-title":"Implications of programmed cell death 1 ligand 1 heterogeneity in the selection of patients with non-small cell lung cancer to receive immunotherapy","volume":"100","author":"Mansfield","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"issue":"November (2)","key":"10.1016\/j.lungcan.2017.01.004_bib0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","article-title":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","volume":"86","author":"Mansfield","year":"2014","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2017.01.004_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"issue":"2016","key":"10.1016\/j.lungcan.2017.01.004_bib0045","article-title":"Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study","volume":"34","author":"Kindler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.01.004_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2017.01.004_bib0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.lungcan.2017.01.004_bib0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00262-014-1563-6","article-title":"B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation","volume":"63","author":"Gibbons","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.lungcan.2017.01.004_bib0065","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.1003976","article-title":"B7-h1 expressed by activated CD8T cells is essential for their survival","volume":"187","author":"Pulko","year":"2011","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.lungcan.2017.01.004_bib0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.01.004_bib0075","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"issue":"November (11)","key":"10.1016\/j.lungcan.2017.01.004_bib0080","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ t cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2017.01.004_bib0085","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic t cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.lungcan.2017.01.004_bib0090","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","article-title":"Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2017.01.004_bib0095","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1158\/1078-0432.CCR-15-2246","article-title":"Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer","volume":"22","author":"Mansfield","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"S1","key":"10.1016\/j.lungcan.2017.01.004_bib0100","first-page":"S150","article-title":"Somatic genetic alterations and immune microenvironment in malignant pleural mesothelioma","volume":"12","author":"Vigneswaran","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.01.004_bib0105","series-title":"Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028 AACR Annual Meeting 2015 Abstract CT103","author":"Alley","year":"2015"},{"issue":"S1","key":"10.1016\/j.lungcan.2017.01.004_bib0110","first-page":"S150","article-title":"Long-Term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028","volume":"12","author":"Alley","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2017.01.004_bib0115","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"April 2\u20138 (10026)","key":"10.1016\/j.lungcan.2017.01.004_bib0120","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lungcan.2017.01.004_bib0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"S1","key":"10.1016\/j.lungcan.2017.01.004_bib0130","first-page":"S149","article-title":"Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis","volume":"12","author":"Kindler","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2017.01.004_bib0135","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.01.004_bib0140","series-title":"CheckMate 026: A Phase 3 Trial of Nivolumab vs Investigator's Choice (IC) of Platinum-Based Doublet Chemotherapy (PT-DC) as First-line Therapy for Stage iv\/Recurrent Programmed Death Ligand 1 (PDl1)-positive NSCLC ESMO 2016 Congress","author":"Socinski","year":"2016"},{"issue":"1","key":"10.1016\/j.lungcan.2017.01.004_bib0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217300041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217300041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T09:23:43Z","timestamp":1568712223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217300041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":29,"alternative-id":["S0169500217300041"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}